Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of PEXG chemotherapy with or without metformin in metastatic pancreatic cancer
2010-020979-23Phase 2Completed
- Sponsor
- Fondazione Centro San Raffaele
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Fondazione Centro San Raffaele. Primary endpoint: Progression-free survival at 6 months. Started Jul 2010; status: completed.
02
Drugs
metformin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-020979-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020979-23.